31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
MDS varied significantly by age, sex, education, and language of administration even among participants with normal cognition. 5 key findings →
Participants: 25,330 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
White matter hyperintensities (WMH) are neuroimaging markers linked to an elevated risk of cognitive decline. 2 key findings →
Participants: 60 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Parental death during childhood is associated with higher prevalence of AD, with different critical periods for father's versus mother's death, with strength of these associations attenuated by remarriage of the widowed parent. 5 key findings →
Participants: 4,108 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
SSRI treatment showed no significant effect on AD dementia progression (hazard ratio = 1.64, 95% confidence interval: 0.61 to 4.38) or cognitive trajectories, regardless of AD pathology. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) and vascular dementia (VaD) exhibit distinct neuropathological hallmarks, with AD defined by cortical amyloid plaques and neurofibrillary tangles, while VaD arises primarily from cerebrovascular disease (CeVD). 4 key findings →
Participants: 531 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results in this study demonstrated that the Zarit Burden Interview is a valid and reliable instrument for measuring the burden of caregivers of PWD in Singapore. 2 key findings →
Participants: 149 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In total, 3028 posts were retrieved, including 1552 from older adult-related subreddits and 1476 from Alzheimer disease-related subreddits; 18 key topics were identified, with the most frequent topics being expressing feelings (2178/3028, 71.93%) and seeking advice and support (1982/3028, 65.46%). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The findings from this study add to the anatomical knowledge of hippocampal subregions in PD, allowing us to understand the unique functional contribution of each subfield. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cerebral atrophy, detected as ventricular enlargement or sulcal widening on MRI, is recognized as a risk factor for vascular dementia or Alzheimer disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Transactive response (TAR) DNA-binding protein 43 (TDP-43) is a critical RNA/DNA-binding protein involved in various cellular processes, including RNA splicing, transcription regulation, and RNA stability. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
SnRNA-seq analysis revealed elevated microglial proportions across all dementia subtypes compared to NCI. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We synthesized caregivers' multiple challenges under five themes - (1) lack of information and awareness limit perceived need for services, (2) cultural norms and values influence decision to seek services, (3) complex processes and long waiting times hinder ability to reach services, (4) financial constraints and high costs force alternate care arrangements, and (5) inability to meet expectations and lack of family support limit engagement with services. 4 key findings →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These findings establish IF as a potent modulator of synaptic resilience in VaD, acting through coordinated preservation of synaptic structure, inhibition of inflammatory synapse loss, and metabolic reprogramming. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 389,314 participants, CKM stages were distributed as follows: stage 0 (10.0%), stage 1 (8.0%), stage 2 (57.6%), stage 3 (17.9%), and stage 4 (6.5%). 5 key findings →
Participants: 389,314 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Currently no specific biomarkers exist for the screening of pregnancies at risk for Down syndrome (DS). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 871 participants (mean age: 62.80 ± 6.02 years), every SD increase in AIx and RI scores was both associated with 0.010 pg/mL (95% CI: 0.003–0.017, p = 0.004) higher blood p-tau217 levels after adjustment for age, employment status, BMI, mild cognitive impairment, hypertension, cholesterol-HDL ratio, renal function, and ApoE4 carrier status. 5 key findings →
Design: cross-sectional Participants: 871 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Forty-four physicians, primarily neurologists (n = 31; 70.5 %), were interviewed. 5 key findings →
Participants: 31 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Patients in this study were from the China Stroke Center Alliance database. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The amyloid-beta (Aβ) peptide is the derivative of amyloid precursor protein (APP) generated through sequential proteolytic processing by β- and γ-secretases. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Using a knowledge-translation framework, information and strategies can be provided to family and professional caregivers to help them optimize residual memory and communication in people with dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In phase 1, the mean system usability scores increased from 65.4 (SD 11.8) in round 1 to 73.8 (SD 15.9) in round 3, exceeding the benchmark of 68. 5 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The implementation of a transmural model of early palliative care for patients with advanced dementia requires the coordination between clinicians in the tertiary care setting and community, together with health information technologists. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Five themes emerged. Both older adults and adult children had partial knowledge of dementia and were able to list learning new things and social activities as cognitively stimulating activities. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This ultra-brief questionnaire enables rapid screening for cognitive impairment (in <1 min) by family members or as part of community geriatric assessments. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Some of the considerations that need to be taken into account in coming to a decision include: Disease prevalence and burden in the country The existing health-care model and system The ratio of health-care providers to patient Cost and health-care funding in the country The current and projected health-care demand and needs The perception of the population on FP s and primary care providers versus that of specialists in hospitals and The networks and strengths of the primary care model in the country. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events